Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 46 for “"Gene correction"”.

  1. Sequence-Specific Gene Correction of Cystic Fibrosis Airway Basal Cells

    … disease resulting from mutations in the CFTR gene which encodes a protein involved in regulating anion trans-epithelial transport. A three-base deletion in CFTR (termed as ΔF508 mutation), wherein CFTR protein is misfolded leading to its pre-mature degradation in the endoplasmic reticulum …

    uthsc Repository record for Sequence-Specific Gene Correction of Cystic Fibrosis Airway Basal Cells (opens in a new tab)

  2. Gene Correction of Limb Girdle Muscular Dystrophy Type 2A Patient-Specific Induced Pluripotent Stem Cells

    … displayed improved in vitro contractile force generation in response to electrical stimulus. Thus, we established a model for in vitro muscle maturation from PS cells. We applied this maturation model for in vitro validation of Calpain 3 (CAPN3) protein expression. CAPN3 mutations are …

    umn Repository record for Gene Correction of Limb Girdle Muscular Dystrophy Type 2A Patient-Specific Induced Pluripotent Stem Cells (opens in a new tab)

  3. Ipsc Based Gene Correction and Disease Model of A New Class of Lgmd Due to Poglut1 Mutation

    … and rescue experiments. Using a CRISPR based gene targeting method, we aimed to correct the point mutation and restore POGLUT1 function, thus restoring Notch signaling activity. Following correction, iPSC-derived gene corrected myogenic cells were differentiated and compared to healthy control …

    uthsc Repository record for Ipsc Based Gene Correction and Disease Model of A New Class of Lgmd Due to Poglut1 Mutation (opens in a new tab)

  4. Transgenic approaches for the investigation of putative airway stem cells as potential targets for gene correction therapy

    Since the discovery of the CFTR gene over a decade ago, Cystic Fibrosis (CF) has been regarded as amenable to intervention by gene therapy. The ultimate aim of gene therapy must be the correction, within cells capable of repopulating the tissue, of the genetic defect in its chromosomal context. …

    edinburgh Repository record for Transgenic approaches for the investigation of putative airway stem cells as potential targets for gene correction therapy (opens in a new tab)

  5. Development of a CRISPR gene correction strategy for aniridia employing a minimally humanized mouse embryonic stem cell-based disease model

    … caused by heterozygous variants in the PAX6 gene. There is no vision-saving therapy, but one exciting approach is the gene editing capabilities of CRISPR systems to permanently correct the genomic variants. Pre-clinical studies to develop such a therapy in animal models face the challenge of …

    ubc Repository record for Development of a CRISPR gene correction strategy for aniridia employing a minimally humanized mouse embryonic stem cell-based disease model (opens in a new tab) Download PDF for Development of a CRISPR gene correction strategy for aniridia employing a minimally humanized mouse embryonic stem cell-based disease model (opens in a new tab)

  6. Comparison of Homology Independent Replacement of Sequences (HIROS) with Prime Editing for Gene Correction of Dilated Cardiomyopathy-Causing Mutations in Human Cardiomyocytes

    CRISPR-based gene editing technologies offer promising approaches for cause-oriented therapies to cure monogenic diseases by deletion, insertion or replacment of sequences in the genome of proliferating cells. While most types of edits can be also installed in post-mitotic cells, such as human …

    fu-berlin Repository record for Comparison of Homology Independent Replacement of Sequences (HIROS) with Prime Editing for Gene Correction of Dilated Cardiomyopathy-Causing Mutations in Human Cardiomyocytes (opens in a new tab)

  7. Gene targeting at and distant from DNA breaks in yeast and human cells

    Here we developed multiple genetic systems through which genetic modifications driven by DNA breaks caused by the I-SceI nuclease can be assayed in the yeast Saccharomyces cerevisiae and in human cells. Using the delitto perfetto approach for site-directed mutagenesis in yeast, we generated …

    gatech Repository record for Gene targeting at and distant from DNA breaks in yeast and human cells (opens in a new tab)

  8. Development of a modular in vivo reporter system for CRISPR-mediated genome editing and its therapeutic applications for rare genetic respiratory diseases

    … sequencing technologies in terms of diagnosing genetic conditions, we have made much less headway in translating this patient information into therapies and effective treatments. Even with recent calls for greater research into personalised treatments for those affected by a rare disease, …

    edinburgh Repository record for Development of a modular in vivo reporter system for CRISPR-mediated genome editing and its therapeutic applications for rare genetic respiratory diseases (opens in a new tab)

  9. Establishment of gene therapy using CRISPR-mediated gene editing for X-linked chronic granulomatous disease in hematopoietic stem cells

    … one in 250,000 individuals, caused by defects in genes encoding the NADPH oxidase (NOX) complex in phagocytes. X-linked CGD (X-CGD) results from mutations in the CYBB gene encoding the gp91phox subunit, impairing the generation of superoxide required for pathogen elimination. Current treatments …

    fu-berlin Repository record for Establishment of gene therapy using CRISPR-mediated gene editing for X-linked chronic granulomatous disease in hematopoietic stem cells (opens in a new tab)

  10. Therapeutic Genome-Editing for Severe Inherited Skin Disorders

    … powerful tool for treating previously incurable genetic disorders through the targeted correction of disease- causing mutations. Epidermolysis bullosa (EB), a group of rare and severe inherited skin fragility disorders, represents an ideal candidate for such emerging gene therapies due to its …

    auckland-ms Repository record for Therapeutic Genome-Editing for Severe Inherited Skin Disorders (opens in a new tab)

  11. Gene Replacement Therapy For Sickle Cell Disease

    … (bp) mutation in the sixth codon of the β-globin gene. It causes severe tissue damage that can result in strokes, splenic infarction, kidney failure, liver and lung disorders, painful crises, and other complications. Currently, the only cure for the disease is allogenic stem cell transplantation, …

    uab Repository record for Gene Replacement Therapy For Sickle Cell Disease (opens in a new tab)

  12. Extending the Longevity of AAV-mediated Lung Gene Therapy

    AAV-mediated gene therapy has progressed rapidly in the past three decades, permitting the use of this vector for the treatment of several diseases. Although the first administration of an AAV vector into a human patient occurred in 1995 to correct cystic fibrosis in the lungs, this organ remains a …

    guelph Repository record for Extending the Longevity of AAV-mediated Lung Gene Therapy (opens in a new tab)

  13. A STEP-BY-STEP PROCESS TO GENERATE FUNCTIONAL OSTEOCLASTS FROM SITE SPECIFIC GENE-CORRECTED INDUCED PLURIPOTENT STEM CELLS: AN AUTOLOGOUS CELL THERAPY APPROACH TO TREAT AUTOSOMAL RECESSIVE OSTEOPETROSIS.

    … of the medullary cavity. Among the heterogeneous group of osteopetrosis, ARO shows the most severe phenotype, leading to death early in life if not treated. The most frequently mutated gene is the T-cell immune regulator 1 (TCIRG1), encoding the a3 subunit of the vacuolar-type proton …

    milano Repository record for A STEP-BY-STEP PROCESS TO GENERATE FUNCTIONAL OSTEOCLASTS FROM SITE SPECIFIC GENE-CORRECTED INDUCED PLURIPOTENT STEM CELLS: AN AUTOLOGOUS CELL THERAPY APPROACH TO TREAT AUTOSOMAL RECESSIVE OSTEOPETROSIS. (opens in a new tab)

  14. Site-Specific Genome Engineering in Mouse Primary Fibroblasts

    … can dramatically stimulate the frequency of gene targeting at a given locus. Recently, there has been an outpouring of studies performing site-specific genome engineering in human cell lines and primary cells, including embryonic stem cells, induced pluripotent stem cells and CD34+ …

    utswmed Repository record for Site-Specific Genome Engineering in Mouse Primary Fibroblasts (opens in a new tab)

  15. Development of Genome Engineering Strategies in Induced Pluripotent Stem Cells to Enable Autologous Transplantation for Duchenne Muscular Dystrophy

    … in the understanding of the disease pathogenesis and testing of novel therapeutics, currently there is still no cure for DMD. Human pluripotent stem cells (hPSCs) are an appealing cell source for the treatment of DMD and other types of muscular dystrophies, given that they have the ability …

    umn Repository record for Development of Genome Engineering Strategies in Induced Pluripotent Stem Cells to Enable Autologous Transplantation for Duchenne Muscular Dystrophy (opens in a new tab)

  16. Durability and Longevity of Gene Edited DMD Skeletal Muscle

    … disease caused by mutations in the dystrophin gene. CRISPR/Cas9 genome editing has been used to correct DMD mutations in animal models at young ages. However, the longevity and durability of CRISPR/Cas9 editing remained to be determined. To address these issues, I subjected ΔEx44 DMD mice to …

    utswmed Repository record for Durability and Longevity of Gene Edited DMD Skeletal Muscle (opens in a new tab)

  17. Site-specific Human CFTR Gene Integration through CRISPR/Cas9-mediated Targeting

    … recessive disease caused by mutations in the gene coding for cystic fibrosis transmembrane conductance regulator (CFTR). It leads to multiple organ dysfunctions, where lung disease is the major cause of morbidity and mortality. Gene therapy for CF lung disease is still challenged with …

    toronto-retro Repository record for Site-specific Human CFTR Gene Integration through CRISPR/Cas9-mediated Targeting (opens in a new tab)

  18. Ex vivo gene therapy using human muscle stem cells and bacterial nanocellulose as a new culture strategy

    … dystrophies (MD) are a group of untreatable degenerative disorders of inherited origin, characterized by progressive muscle wasting and short life expectancy. Cell-based therapy holds the promise to repopulated and restore the dystrophic muscle after allogeneic or autologous transplantation. …

    fu-berlin Repository record for Ex vivo gene therapy using human muscle stem cells and bacterial nanocellulose as a new culture strategy (opens in a new tab)

  19. Clonal dynamics of somatic evolution and gene therapy in cancer predisposition syndromes

    … at elevated cancer risks compared to the general population. In this dissertation, I first investigate how an inherited TP53 pathogenic variant alters the somatic evolutionary dynamics across normal tissues in a family with Li-Fraumeni syndrome, a cancer predisposition syndrome associated …

    washington Repository record for Clonal dynamics of somatic evolution and gene therapy in cancer predisposition syndromes (opens in a new tab)

Page 1 of 3